Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Inclusion Criteria: * Capable of understanding and complying with the protocol requirements and must have signed the informed consent document * Agreement to allow the use of archival tissue from diagnostic tumor biopsies * If unavailable, exceptions may be granted with study principal investigator (PI) approval * Age: ≥ 18 years * Gender: Males and females are eligible * Any ethnicity or race * Eastern Cooperative Oncology Group (ECOG) ≤ 2 * Histologically confirmed renal cell carcinoma with a clear-cell histology * Patients must have received one or two prior lines of systemic therapy for metastatic disease, which must include prior treatment with a checkpoint inhibitor and cabozantinib (not necessarily in the same line). Prior use of hypoxia-inducible factor (HIF) inhibitors or other tyrosine kinase inhibitors (TKIs) other than cabozantinib are not allowed * Measurable metastatic disease by RECIST v 1.1 criteria * Recovery to baseline or ≤ grade 1 severity (CTCAE v 6.0) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy (e.g., physiological replacement of corticosteroid). Low-grade or controlled toxicities such as alopecia, ≤ grade 2 hypomagnesemia, ≤ grade 2 neuropathy are permitted) * White blood cell (WBC) \> 2,000/mm\^3 (to be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated) * NOTE: Growth fa…